MARZIO, Leonardo
 Distribuzione geografica
Continente #
NA - Nord America 5.199
EU - Europa 4.768
AS - Asia 3.107
SA - Sud America 167
Continente sconosciuto - Info sul continente non disponibili 17
AF - Africa 15
OC - Oceania 6
Totale 13.279
Nazione #
US - Stati Uniti d'America 5.166
CN - Cina 1.071
UA - Ucraina 968
SG - Singapore 892
IE - Irlanda 770
IT - Italia 698
TR - Turchia 683
SE - Svezia 626
GB - Regno Unito 531
FR - Francia 430
IN - India 372
DE - Germania 292
FI - Finlandia 192
BR - Brasile 148
RU - Federazione Russa 134
PL - Polonia 37
VN - Vietnam 35
CA - Canada 19
BE - Belgio 17
EU - Europa 17
RO - Romania 14
MX - Messico 13
CZ - Repubblica Ceca 10
GR - Grecia 10
HK - Hong Kong 9
IL - Israele 8
NL - Olanda 7
AT - Austria 6
AU - Australia 6
IQ - Iraq 6
AL - Albania 5
EC - Ecuador 5
IR - Iran 5
KR - Corea 5
PK - Pakistan 5
AR - Argentina 4
ES - Italia 4
PT - Portogallo 4
CH - Svizzera 3
CL - Cile 3
EG - Egitto 3
ID - Indonesia 3
KE - Kenya 3
LT - Lituania 3
NO - Norvegia 3
TW - Taiwan 3
ZA - Sudafrica 3
BO - Bolivia 2
CO - Colombia 2
DZ - Algeria 2
MA - Marocco 2
SC - Seychelles 2
VE - Venezuela 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
JM - Giamaica 1
JP - Giappone 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
Totale 13.279
Città #
Jacksonville 1.078
Chandler 779
Dublin 758
Singapore 487
Dearborn 458
Southend 422
Princeton 386
Izmir 333
Nanjing 327
Wilmington 257
Cambridge 181
Beijing 157
Woodbridge 118
Ashburn 114
Ann Arbor 113
The Dalles 107
Nanchang 104
Santa Clara 94
Boardman 65
Shenyang 62
Houston 61
New York 60
Hebei 56
Altamura 54
Kunming 49
Tianjin 46
Jiaxing 44
Rome 43
Los Angeles 37
Kraków 36
Chieti 35
Hangzhou 31
Jinan 26
Bologna 25
Norwalk 24
Grevenbroich 22
Hefei 22
Dong Ket 20
Guangzhou 20
Orange 20
Changsha 19
Milan 17
Brussels 16
Helsinki 16
Washington 16
Düsseldorf 15
Vinh 14
Augusta 13
São Paulo 13
Changchun 12
Lanzhou 12
Pescara 11
San Mateo 11
Ningbo 10
Cepagatti 9
Fuzhou 9
Guadalajara 9
Hong Kong 9
Moscow 9
Brno 8
L'aquila 8
Toronto 8
Zhengzhou 8
Bellante 7
Brasília 7
London 7
Munich 7
Seattle 7
Kocaeli 6
Tappahannock 6
Varallo 6
Auburn Hills 5
Belo Horizonte 5
Edinburgh 5
Frankfurt am Main 5
Leawood 5
Siena 5
Taizhou 5
Turin 5
Villamagna 5
Cedar Knolls 4
Guayaquil 4
Isernia 4
Melbourne 4
Nuremberg 4
Palermo 4
Pompei 4
Redwood City 4
Sulmona 4
Walnut 4
Xian 4
Avezzano 3
Baghdad 3
Baotou 3
Cairo 3
Castelfranco di Sotto 3
Caxias do Sul 3
Falls Church 3
Haikou 3
Limeil-brévannes 3
Totale 7.572
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 364
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 157
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 123
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 122
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 118
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 117
24-hour pancolonic motility using a portable electronic probe in healthy subjects 116
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 114
Antibacterial effect of plant extracts against Helicobacter pylori 112
Trasmissione di Helicobacter pylori in un modello murino 109
Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. 106
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 105
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 104
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 103
Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. 103
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 101
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 101
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 100
Heightened free radical activity in angina pectoris 99
L'eritromicina accelera lo svuotamento gastrico e colecistico nell'uomo attraverso un meccanismo mediato dall'acetilcolina 99
Circadian variations in antioxidant defences and lipid peroxidation in the rat heart 98
Anti-H pylori specific antibody immunoistochemistry improves the diagnostic accuracy of H piylori in biopsy specimen from patients treated with triple therapy 97
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 97
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 97
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 95
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 94
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 93
Triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacte pylori infection. A double blind placebo controlled trial. 93
Uso razionale di schemi terapeutici nelle infezioni da Helicobacter pylori 93
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 93
Coccoid Helicobacter pylori not culturable in vitro reverts in mice. 92
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 91
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 91
Cigarette smoke, ferritin, and lipid peroxidation 91
Blood cardioplegia reduces oxidant burden in the ischemic and reperfused human myocardium 91
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 88
Effects of combining extracts (from Propolis or Zingiber officinale) with Clarithromycin on H.pylori. 88
Detection of Helicobacter pylori in saliva and esophagus 88
Masse all'ipocondrio dx e carcinoma della colecisti 88
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 87
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 87
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 85
Detection of Helicobacter pylori in esophagus and saliva in humans 85
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 85
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 84
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 84
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 83
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 83
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 82
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 82
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 82
[Physiopathological bases of the medical treatment of portal hypertension]. 82
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 82
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 82
Esophageal and gastric motility in patients with gastroesophageal reflux disease 81
Effect of ischemia and reperfusion on antioxidant enzymes and mitochondrial inner membrane proteins in perfused rat heart. 81
Heparin: does it act as an antioxidant in vivo? 81
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 81
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 81
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 80
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 80
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 79
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 78
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 78
Rifabutin based triple therapy for eradication of H.pylori primary and secondary resistant to tinidazole and clarithromycin 78
LA MALDIGESTIONE 78
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 78
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 77
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 77
Identification of a novel mutation affecting domain V of the 23S rRNA gene in Helicobacter pylori 77
Aortic glutathione-related antioxidant defences in rabbits subjected to suprarenal aortic coarctation hypertension 77
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 76
null 76
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 75
Role of U.S. and oral colecistography in pre-operative diagnostic approach to cholelithiasis 75
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 74
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 74
Influence of physical activity on gastric emptying of liquids in normal human subjects 74
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 74
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 74
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 74
Changes in the myocardial enzymatic systems (AES) induced by ischemia-reperfusion in the isolated rat heart 74
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 73
Regional distribution of glutathione-related antioxidant defences in the normal rabbit aorta. 73
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 73
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 73
THE VALUE OF CONTRAST ENHANCED ENDOSCOPIC ULTRASOUND IN THE FINE NEEDLE ASPIRATION 73
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 72
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 72
La terapia chirurgica laparoscopica della malattia da reflusso gastro-esofageo 71
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 71
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 71
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 71
Mouth to caecum transit time (MCTT) is accellerated after oral food antigen in patients with irritable bowel syndrome 71
EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS 71
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 70
ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE 70
Prolonged anal sphincter manometry in normal human subjects 69
EVALUATION OF FIBROSIS AND INTRAPARENCHIMAL BLOOD FLOW INCHIRROTIC PATIENTS, CHRONIC ACTIVE HEPATITIS AND NORMAL CONTROLS THROUGH FIBROSCAN AND ULTRASOUND ENHANCED CONTRAST MEDIA. 69
Registrazione delle 24 ore della motilità del piloro in soggetti normali 68
Totale 8.929
Categoria #
all - tutte 50.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.944


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020224 0 0 0 0 0 0 0 0 0 0 224 0
2020/20211.118 187 5 188 10 87 239 14 18 80 190 23 77
2021/2022794 28 12 6 200 75 9 10 65 55 6 89 239
2022/20232.220 199 234 122 268 186 514 150 160 259 29 54 45
2023/20241.019 77 52 65 29 33 313 252 40 3 41 17 97
2024/20251.785 189 410 308 38 65 67 48 161 335 110 54 0
Totale 13.537